Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

V-902

Supelco

Vardenafil dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H32N6O4S·2HCl
Número de CAS:
224785-90-4
Peso molecular:
561.52
EC Number:
200-659-6
MDL number:
MFCD04972607
UNSPSC Code:
41116107
PubChem Substance ID:
329830239
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

SMILES string

O=C(C1=C(C)N=C(CCC)N1N2)N=C2C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC.Cl.Cl

InChI

1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

InChI key

NOIHTGOGFDFCBN-UHFFFAOYSA-N

Gene Information

human ... PDE5A(8654)

General description

Vardenafil, a phosphodiesterase inhibitor, is used to treat erectile dysfunction. This Snap-N-Spike® reference solution is applicable for use in urine drug testing, clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Vardenafil is sold under the trade names Levitra® and Staxyn®.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Levitra is a registered trademark of Bayer Aktiengesellschaft
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Staxyn is a registered trademark of Bayer Aktiengesellschaft

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 2

1 of 2

Sildenafil Citrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1807

Sildenafil Citrate

Sildenafil citrate European Pharmacopoeia (EP) Reference Standard

Y0001578

Sildenafil citrate

I A Korneev
Urologiia (Moscow, Russia : 1999), (2)(2), 106-108 (2013-06-26)
The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil--levitra ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of
Kristina Y Rust et al.
Therapeutic drug monitoring, 34(6), 729-735 (2012-11-07)
Phosphodiesterase type 5 inhibitors such as sildenafil, vardenafil, and tadalafil are a class of drugs used primarily in the treatment of erectile dysfunction. Sildenafil and tadalafil are also approved for the treatment of pulmonary hypertension. The aim of this study
O A H Reneerkens et al.
Psychopharmacology, 225(2), 303-312 (2012-08-03)
Sensory gating is an adaptive mechanism of the brain to prevent overstimulation. Patients suffering from clinical disorders such as Alzheimer's disease or schizophrenia exhibit a deficit in gating, which indicates not only an impairment in basic information processing that might
Osama Shaeer
The journal of sexual medicine, 10(2), 532-540 (2012-10-24)
Utility of phosphodiesterase inhibitors (PDEi's) for the treatment of erectile dysfunction (ED) has been the focus of experimental and clinical studies. However, public preferences, attitudes, and experiences with PDEi's are rarely addressed from a population/epidemiology viewpoint. The Global Online Sexuality
JinQiu Yuan et al.
European urology, 63(5), 902-912 (2013-02-12)
Phosphodiesterase type 5 inhibitors (PDE5-Is) are currently the first-line therapy for erectile dysfunction (ED), but available studies investigating the comparative effects of different PDE5-Is are limited. To compare the efficacy and safety of different classes of oral PDE5-Is for ED.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico